Lupin and Takeda to commercialise Vonoprazan in India

Lupin has announced a non-exclusive patent licence agreement with Takeda for the commercialisation of Vonoprazan Tablets in India.

Sep 20, 2024 - 04:00

Lupin and Takeda to commercialise Vonoprazan in India

Lupin has announced a non-exclusive patent licence agreement with Takeda for the commercialisation of Vonoprazan Tablets in India.

Read the original article

Tags:

Previous Article

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

FDA approves Accord BioPharma’s HERCESSI for cancer treatment

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Diabesity: Overlapping pathophysiology informs multi-indication treatment

Diabesity: Overlapping pathophysiology informs multi-in...

Aug 15, 2024

The Future for Biotesting

The Future for Biotesting

Apr 16, 2023

Cipla sees highest patent filings and grants during Sep...

Dec 10, 2023